Q-omics provides the consensus-scored LRRFIP1 profile across patient tissues and cancer cell-line models. LRRFIP1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, LRRFIP1 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, LRRFIP1 protein abundance shows 29,341 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, BLCA, and GBM as cancer lineages where LRRFIP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRFIP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRFIP1 survival associations across molecular data types. LRRFIP1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRFIP1 RNA expression–survival associations across cancer types. High LRRFIP1 expression shows unfavorable associations in MESO, LGG, ACC, KIRP, KICH and LUAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify MESO as the clearest survival context for LRRFIP1 RNA expression.
This table summarizes LRRFIP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in BLCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for LRRFIP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRFIP1 shows lower tumor expression in BLCA, KICH, THCA, LUSC and LUAD and higher tumor expression in HNSC. The BLCA box plot shows higher LRRFIP1 RNA expression in normal versus tumor tissue (log2 FC = −1.167, t-test p < 0.001).
This table shows molecular features associated with LRRFIP1 in patient tissues and cancer cell lines. In patient samples, LRRFIP1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRFIP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
